A Randomized Phase II Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Latest Information Update: 05 May 2023
At a glance
- Drugs Fludarabine (Primary) ; Treosulfan (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 13 May 2021 Planned End Date changed from 1 Jan 2022 to 1 Jun 2022.
- 30 Aug 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Feb 2017.
- 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.